

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Health Technology Appraisal

#### Maribavir for treating refractory or resistant cytomegalovirus infection after transplant ID3900

#### Provisional stakeholder list of consultees and commentators

| Consultees   | Commentators (no right to submit or appeal)   |
|--|---|
| <p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Takeda (maribavir)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• African Caribbean Leukaemia Trust (ACLT)</li> <li>• Anthony Nolan</li> <li>• Aplastic Anaemia Trust</li> <li>• Blood Cancer UK</li> <li>• DKMS</li> <li>• Heart UK</li> <li>• Kidney Care UK</li> <li>• Kidney Research UK</li> <li>• Leukaemia Care</li> <li>• Leukaemia Cancer Society</li> <li>• Liver4Life</li> <li>• Lymphoma Action</li> <li>• Myeloma UK</li> <li>• National Kidney Federation</li> <li>• Pumping Marvellous Foundation</li> <li>• Sommerville Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Clinical Biochemists - Microbiology Section</li> <li>• British Geriatrics Society</li> <li>• British Infection Association</li> <li>• Infection Prevention Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> </ul> | <p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (valganciclovir)</li> <li>• Aurobindo Pharma - Milpharm (valganciclovir)</li> <li>• Cheplapharm Arzneimittel (ganciclovir)</li> <li>• Cipla (valganciclovir)</li> <li>• Clinigen Healthcare (foscarnet)</li> <li>• Glenmark Pharmaceuticals (valganciclovir)</li> <li>• Mylan (valganciclovir)</li> <li>• Roche (valganciclovir)</li> </ul> |

Provisional stakeholder list for the health technology appraisal of maribavir for treating refractory or resistant cytomegalovirus infection after transplant ID3900

Issue date: April 2021

© National Institute for Health and Care Excellence 2021. All rights reserved.

Page 1 of 3

| <b>Consultees</b>   | <b>Commentators (no right to submit or appeal)</b>   |
|---|--|
| <ul style="list-style-type: none"> <li>• Royal Society of Medicine</li> <li>• Society for General Microbiology</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Bolton CCG</li> <li>• NHS Bradford City CCG</li> <li>• NHS England</li> <li>• Welsh Government</li> </ul> | <ul style="list-style-type: none"> <li>• Thea Pharmaceuticals (ganciclovir)</li> <li>• Tillomed Laboratories (cidofovir)</li> <li>• Zentiva (valganciclovir)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Infectious Diseases Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul> |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## Definitions:

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.